Get the Stockscreener App
144.63
0.08%
-0.11
After Hours:
145.00
0.37
+0.26%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $144.63, with a volume of 5.68M.
It is down -0.08% in the last 24 hours and down -4.22% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$144.74
Open:
$143.21
24h Volume:
5.68M
Relative Volume:
0.92
Market Cap:
$179.33B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
19.68
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
-4.98%
1M Performance:
-4.22%
6M Performance:
+3.52%
1Y Performance:
+28.34%
1-Day Range:
$142.79
$145.16
1-Week Range:
$142.79
$152.62
52-Week Range:
$112.41
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
144.63 | 179.47B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,143.12 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
252.93 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.76 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
139.54 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
140.93 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
More Upside Awaits for Gilead Sciences Stock. Stay Invested. - Barron's
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Gilead expands lenacapavir licenses: Gilead Sciences stock has 6.53 percent upside - AD HOC NEWS
Gilead Sciences stock pre-market at EUR 131.75: plus 0.54 percent - AD HOC NEWS
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance
Gilead Sciences, Inc. (GILD) stock price, news, quote and history - uk.finance.yahoo.com
Gilead Sciences (NASDAQ:GILD) Stock: Stronger HIV Sales Meet Weaker Reported Earnings - kalkine.ca
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase? - Yahoo Finance
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside? - Yahoo Finance
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? - Yahoo Finance
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend? - Yahoo Finance
Gilead Sciences (GILD) Share Price, News, Stock Market Cap NASDAQ - TechGraph
CEUX:GISd Dividend: Does Gilead Sciences Inc Pay a Dividend? - GuruFocus
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? - Insider Monkey
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - Yahoo Finance
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? - Yahoo Finance
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? - Insider Monkey
Form 4 Gilead Sciences Inc For: 26 September By Investing.com - Investing.com Nigeria
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts - MarketBeat
Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close - AD HOC NEWS
UBS Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
Gilead Sciences stock falls 1.11 percent despite revenue growth - AD HOC NEWS
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc. - MarketBeat
Gilead Sciences stock heads into the open after a 0.4 percent gain - AD HOC NEWS
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Form DEF 14A Gilead Sciences Inc For: 24 September By Investing.com - Investing.com Canada
Gilead Sciences stock slips 0.85 percent ahead of the open - AD HOC NEWS
Gilead: HIV Growth Is Not Enough At The Current Price (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences stock slips 1.30 percent at the close - AD HOC NEWS
Gilead Sciences, Inc. (GILD) latest stock news and headlines - Yahoo Finance Singapore
Gilead Sciences stock slips as earnings estimates shift - AD HOC NEWS
Can Gilead Sciences (NASDAQ:GILD) turn HIV leadership and oncology development into a stronger market story? - Kalkine Media
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead Sciences stock slips 0.7 percent ahead of the open - AD HOC NEWS
Gilead Sciences Research Scholars Program in Solid Tumors – US 2026 - Oncodaily
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know - Yahoo Finance
Gilead Sciences stock slips 0.7 percent at the close - AD HOC NEWS
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Andra AP fonden Sells 11,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences stock holds near 52-week high as HIV prevention deal and analyst optimism support va - AD HOC NEWS
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Erste Group Bank Estimates Gilead Sciences FY2027 Earnings - MarketBeat
Gilead Sciences stock heads into the open after a 0.52% dip - ad-hoc-news.de
Gilead Sciences stock gains as HIV drug access expands - AD HOC NEWS
Why Morgan Stanley likes Gilead’s HIV prevention play - thestreet.com
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries? - Yahoo Finance
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
0.59%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):